Drug Profile


Alternative Names: GS-333126; GS-9190

Latest Information Update: 04 Aug 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Gilead Sciences
  • Class Antivirals
  • Mechanism of Action Hepatitis C virus NS 5 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Hepatitis C

Most Recent Events

  • 05 Sep 2011 Gilead terminates dosing of tegobuvir in patients receiving four-drug regimens in ongoing trials
  • 17 May 2011 Gilead Sciences completes enrolment in its phase II trial for Hepatitis C in Austria, Belgium, Canada, Czech Republic, England, France, Germany, Italy, Poland, Spain and USA (NCT01225380)
  • 03 Apr 2011 Efficacy and adverse events data from a phase IIb trial in Hepatitis C) presented at the 46th Annual Meeting of the European Association for the Study of the Liver (EASL-2011)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top